191 related articles for article (PubMed ID: 24002592)
1. Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer.
Pfeiler G; Königsberg R; Hadji P; Fitzal F; Maroske M; Dressel-Ban G; Zellinger J; Exner R; Seifert M; Singer C; Gnant M; Dubsky P
Br J Cancer; 2013 Sep; 109(6):1522-7. PubMed ID: 24002592
[TBL] [Abstract][Full Text] [Related]
2. Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole.
Kyvernitakis I; Knöll D; Struck M; Hars O; Bauer T; Hadji P
J Cancer Res Clin Oncol; 2014 Jan; 140(1):159-66. PubMed ID: 24292402
[TBL] [Abstract][Full Text] [Related]
3. Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors.
Lønning PE; Haynes BP; Dowsett M
Eur J Cancer; 2014 Apr; 50(6):1055-64. PubMed ID: 24507547
[TBL] [Abstract][Full Text] [Related]
4. Does obesity interfere with anastrozole treatment? Positive association between body mass index and anastrozole plasma levels.
Hubalek M; Oberguggenberger A; Beer B; Meraner V; Sztankay M; Oberacher H; Schubert B; Wildt L; Seeber B; Giesinger J; Kemmler G; Holzner B; Sperner-Unterweger B
Clin Breast Cancer; 2014 Aug; 14(4):291-6. PubMed ID: 24468298
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index.
Sendur MA; Aksoy S; Zengin N; Altundag K
Br J Cancer; 2012 Nov; 107(11):1815-9. PubMed ID: 23099804
[TBL] [Abstract][Full Text] [Related]
6. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.
Folkerd EJ; Dixon JM; Renshaw L; A'Hern RP; Dowsett M
J Clin Oncol; 2012 Aug; 30(24):2977-80. PubMed ID: 22802308
[TBL] [Abstract][Full Text] [Related]
7. Can we use gonadotropin plasma concentration as surrogate marker for BMI-related incomplete estrogen suppression in breast cancer patients receiving anastrozole?
Oberguggenberger A; Meraner V; Sztankay M; Beer B; Weigel G; Oberacher H; Kemmler G; Czech T; Holzner B; Wildt L; Sperner-Unterweger B; Daniaux M; Hubalek M
BMC Cancer; 2017 Mar; 17(1):226. PubMed ID: 28351392
[TBL] [Abstract][Full Text] [Related]
8. Estrone and Estradiol Levels in Breast Cancer Patients Using Anastrozole Are Not Related to Body Mass Index.
Coscia EB; Sabha M; Gerenutti M; Groppo FC; Bergamaschi CC
Rev Bras Ginecol Obstet; 2017 Jan; 39(1):14-20. PubMed ID: 28187491
[No Abstract] [Full Text] [Related]
9. Aromatase inhibitors in obese breast cancer patients are not associated with increased plasma estradiol levels.
Diorio C; Lemieux J; Provencher L; Hogue JC; Vachon E
Breast Cancer Res Treat; 2012 Nov; 136(2):573-9. PubMed ID: 23053662
[TBL] [Abstract][Full Text] [Related]
10. Obesity and endocrine therapy: host factors and breast cancer outcome.
Goodwin PJ
Breast; 2013 Aug; 22 Suppl 2():S44-7. PubMed ID: 24074791
[TBL] [Abstract][Full Text] [Related]
11. Incidence and Predictive Factors for Recovery of Ovarian Function in Amenorrheic Women in Their 40s Treated With Letrozole.
Krekow LK; Hellerstedt BA; Collea RP; Papish S; Diggikar SM; Resta R; Vukelja SJ; Holmes FA; Reddy PK; Asmar L; Wang Y; Fox PS; Peck SR; O'Shaughnessy J
J Clin Oncol; 2016 May; 34(14):1594-600. PubMed ID: 26884554
[TBL] [Abstract][Full Text] [Related]
12. Serum estradiol should be monitored not only during the peri-menopausal period but also the post-menopausal period at the time of aromatase inhibitor administration.
Nagao T; Kira M; Takahashi M; Honda J; Hirose T; Tangoku A; Zembutsu H; Nakamura Y; Sasa M
World J Surg Oncol; 2009 Nov; 7():88. PubMed ID: 19909552
[TBL] [Abstract][Full Text] [Related]
13. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.
Geisler J; Haynes B; Anker G; Dowsett M; Lønning PE
J Clin Oncol; 2002 Feb; 20(3):751-7. PubMed ID: 11821457
[TBL] [Abstract][Full Text] [Related]
14. Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy.
Santen RJ; Demers L; Ohorodnik S; Settlage J; Langecker P; Blanchett D; Goss PE; Wang S
Steroids; 2007 Jul; 72(8):666-71. PubMed ID: 17588628
[TBL] [Abstract][Full Text] [Related]
15. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Dixon JM; Renshaw L; Young O; Murray J; Macaskill EJ; McHugh M; Folkerd E; Cameron DA; A'Hern RP; Dowsett M
J Clin Oncol; 2008 Apr; 26(10):1671-6. PubMed ID: 18375896
[TBL] [Abstract][Full Text] [Related]
16. Effect of anastrozole on hormone levels in postmenopausal women with early breast cancer.
Kyvernitakis I; Albert US; Kalder M; Winarno AS; Hars O; Hadji P
Climacteric; 2015 Feb; 18(1):63-8. PubMed ID: 24884402
[TBL] [Abstract][Full Text] [Related]
17. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
Geisler J; King N; Dowsett M; Ottestad L; Lundgren S; Walton P; Kormeset PO; Lønning PE
Br J Cancer; 1996 Oct; 74(8):1286-91. PubMed ID: 8883419
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients.
Bertelsen BE; Viste K; Helland T; Hagland M; Søiland H; Geisler J; Lende TH; Lønning PE; Sagen JV; Mellgren G; Almås B
J Clin Endocrinol Metab; 2022 Apr; 107(5):1368-1374. PubMed ID: 34958096
[TBL] [Abstract][Full Text] [Related]
19. Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole--of clinical importance?
Geisler J
Br J Cancer; 2011 Mar; 104(7):1059-66. PubMed ID: 21364577
[TBL] [Abstract][Full Text] [Related]
20. Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole.
Sini V; Lunardi G; Cirillo M; Turazza M; Bighin C; Giraudi S; Levaggi A; Piccioli P; Bisagni G; Gnoni R; Stridi G; Porpiglia M; Picardo E; Ponzone R; Marenco D; Mansutti M; Puglisi F; Del Mastro L
Br J Cancer; 2014 Mar; 110(5):1133-8. PubMed ID: 24448359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
